About: BACKGROUND: During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to surgery (TTS), pathological staging and overall survival (OS). STUDY DESIGN: Patients with DCIS or ER+ cT1-2N0 breast cancer treated 2010-2016 were identified in the National Cancer Database. TTS was recorded. Factors associated with pathological upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy. RESULTS: 378,839 patients were identified. Among those undergoing primary surgery, TTS was within 120 days in >98% in all groups. Among cT1-2N0 patients selected for NET, surgery was performed within 120 days in 59.6% of cT1N0 and 30.9% of cT2N0 patients. Increased TTS was associated with increased odds of pathological upstaging in DCIS patients (ER+: 60-120 days: OR:1.15, 95% CI:1.08-1.22; >120 days: OR:1.44, 95% CI:1.24-1.68; ER-: 60-120 days: NS; >120 days: OR:1.36, 95% CI:1.01-1.82; <60 days: reference), but not in patients with invasive cancer irrespective of initial treatment strategy. No difference in OS was seen by TTS in DCIS or NET patients. CONCLUSION: Increased TTS was associated with a small increase in pathological upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : wasabi.inria.fr associated with source document(s)

AttributesValues
type
value
  • BACKGROUND: During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to surgery (TTS), pathological staging and overall survival (OS). STUDY DESIGN: Patients with DCIS or ER+ cT1-2N0 breast cancer treated 2010-2016 were identified in the National Cancer Database. TTS was recorded. Factors associated with pathological upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy. RESULTS: 378,839 patients were identified. Among those undergoing primary surgery, TTS was within 120 days in >98% in all groups. Among cT1-2N0 patients selected for NET, surgery was performed within 120 days in 59.6% of cT1N0 and 30.9% of cT2N0 patients. Increased TTS was associated with increased odds of pathological upstaging in DCIS patients (ER+: 60-120 days: OR:1.15, 95% CI:1.08-1.22; >120 days: OR:1.44, 95% CI:1.24-1.68; ER-: 60-120 days: NS; >120 days: OR:1.36, 95% CI:1.01-1.82; <60 days: reference), but not in patients with invasive cancer irrespective of initial treatment strategy. No difference in OS was seen by TTS in DCIS or NET patients. CONCLUSION: Increased TTS was associated with a small increase in pathological upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic.
Subject
  • Oncology
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software